0001209191-19-056372.txt : 20191113
0001209191-19-056372.hdr.sgml : 20191113
20191113163020
ACCESSION NUMBER: 0001209191-19-056372
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191112
FILED AS OF DATE: 20191113
DATE AS OF CHANGE: 20191113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CAGNONI PABLO J
CENTRAL INDEX KEY: 0001205703
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 191214390
MAIL ADDRESS:
STREET 1: ONYX PHARMACEUTICALS, INC.
STREET 2: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-12
0
0001674416
CRISPR Therapeutics AG
CRSP
0001205703
CAGNONI PABLO J
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Shares
2019-11-12
4
M
0
7500
5.59
A
7500
D
Common Shares
2019-11-12
4
S
0
7500
55.00
D
0
D
Stock Option (Right to Buy)
5.59
2019-11-12
4
M
0
7500
0.00
D
2025-11-04
Common Shares
7500
71333
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.
/s/ Michael Esposito, attorney-in-fact
2019-11-13